- Home
- BIIB vs PBA Comparison
BIIB vs PBA Comparison
Compare BIIB & PBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PBA
- Stock Information
- Founded
- BIIB 1978
- PBA 1997
- Country
- BIIB United States
- PBA Canada
- Employees
- BIIB N/A
- PBA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PBA Oil & Gas Production
- Sector
- BIIB Health Care
- PBA Energy
- Exchange
- BIIB Nasdaq
- PBA Nasdaq
- Market Cap
- BIIB 25.1B
- PBA 24.0B
- IPO Year
- BIIB 1991
- PBA N/A
- Fundamental
- Price
- BIIB $159.17
- PBA $40.48
- Analyst Decision
- BIIB Buy
- PBA Buy
- Analyst Count
- BIIB 25
- PBA 1
- Target Price
- BIIB $258.57
- PBA $57.00
- AVG Volume (30 Days)
- BIIB 1.6M
- PBA 1.1M
- Earning Date
- BIIB 10-30-2024
- PBA 11-05-2024
- Dividend Yield
- BIIB N/A
- PBA 4.96%
- EPS Growth
- BIIB 10.05
- PBA 51.43
- EPS
- BIIB 11.06
- PBA 2.43
- Revenue
- BIIB $9,607,500,000.00
- PBA $7,305,229,650.00
- Revenue This Year
- BIIB N/A
- PBA N/A
- Revenue Next Year
- BIIB N/A
- PBA $15.54
- P/E Ratio
- BIIB $14.55
- PBA $16.53
- Revenue Growth
- BIIB N/A
- PBA 37.18
- 52 Week Low
- BIIB $153.62
- PBA $32.39
- 52 Week High
- BIIB $268.30
- PBA $43.44
- Technical
- Relative Strength Index (RSI)
- BIIB 41.81
- PBA 39.02
- Support Level
- BIIB $159.12
- PBA $39.88
- Resistance Level
- BIIB $165.29
- PBA $41.54
- Average True Range (ATR)
- BIIB 3.25
- PBA 0.66
- MACD
- BIIB 1.25
- PBA -0.20
- Stochastic Oscillator
- BIIB 70.36
- PBA 14.89
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.